"Strategic prioritisation on discovery platform and commercialisation
22 March 2016: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces its full year results for the year ended 31 January 2016.
· Highly productive discovery platform
- Strategic focus for the business, now fully developed and generating many potent compounds
- 12 active projects (FY15: 6) and three projects in lead optimisation (FY15: nil)
· ETS6103 - detailed update on analysis of Phase IIb trial results
- Confirmed antidepressant activity for SSRI non-responders
- Fewer side effects and better tolerance profile than current post-SSRI treatment
· ETS2101 - refocus from infused form to explore oral form
- Early phase experimental clinical trials completed
- New data suggests potential for compound when given without a steroid pre-med
· Board changes - appointment of Professor Trevor Jones as Non-Executive Director and Iain Ross as Non-Executive Chairman
· Prioritisation of asset commercialisation - progressing more projects from discovery platform and seeking partners for assets
· Net cash at £24.8m (FY15: £33.8m)
· Operating loss of £11.6m (FY15: loss of £10.2m)
· R&D tax credit of £2.5m (FY15: £2.0m)
· Discovery spend was £4.3m (FY15: £2.7m) due to the increase in number of active projects
Professor Malcolm Young, CEO of e-Therapeutics, said:
"This has been a very productive year for our discovery platform which continues to exceed our expectations by generating high quality, potent compounds. Some of these programmes have the potential to be game changers in immuno-oncology, cancer drug-resistance and anti-infection.
"Detailed analysis of the Phase IIb clinical data for ETS6103 has confirmed its effectiveness as an anti-depressant for patients who have not responded to an SSRI. Early stage exploratory clinical trials on ETS2101 have established an acceptable dose for this product candidate and important information concerning the potential route of administration.
"Our main priorities are to drive the productivity of the discovery platform further and realise shareholder value through the commercialisation of our assets. We maintain a healthy cash position in support of our strategy."
Many reasons...most likely, pi's are afraid to lose their profits and sell on any spike no matter how good the news? Traders and shorters don't help either. However, sometimes the market expects more and seemingly good news is the catalyst to sell or be left holding the baby, imo
Thanks to all those that have supported this campaign
Campaign to make short-selling illegal (or better regulated?)
It is estimated that over 90% of AIM stocks are INFECTED by short-sellers !
Many highly popular stocks are going down even on GOOD NEWS !
# IF you were a short-seller, BLUFFING, (basically manipulating a shares' price) about a company's overvalued share price, you might not want to *draw attention to yourself since you could get accused of stock manipulation. So you would hope (OR PLAN FOR) others to get involved and to present SEEMINGLY GOOD REASONS to short the stock.
You would want to put AS MUCH FEAR INTO 'LONGS' as possible and would use high volume short trading as well as buying to drive the share price down as low as you can and as long as you can. You really want the longs to fold and to get out of the game. If you are consistently seeing sellers overwhelming buyers driving a share price down as a stock seems to be going up, I can assure you it's probably shorts' selling, since longs are totally motivated to sell their shares at the highest possible selling price. #
IT is easier to tank a share price, rather than make it go UP, by short-selling.
RUINOUS to genuine investors.
They may be able to buy in cheap BUT what's the good, if the stock never really recovers?
AND when they have got you all hooked on the 'lovely' new all-time LOW.....They'll SHORT IT AGAIN !
# ChalieHarper - posted on iii - TRP
IF a fund owns a large share holding in a firm and is long.... whilst waiting for its end game to materialise, it loans out any number of its shares to a shorter...the shorter then manipulate the share price down making £X amount when short ended.... the shorter then gives the loaned shares back and splits the proceeds 50/50.
They both make cash, probably during a time when not much is happening with the sp. IT's a WIN-WIN for them but BAD news for the pi's who as usual may have sold at a loss because the cash has to come from somewhere. #
# Topalov asks on iii Ariana Res-AAU
(to give balance to this debate, i have included his response and Q.s with my reply)
Daniel Elger, CFO of e-Therapeutics (LON:ETX), tells Proactiveinvestors that the recent preliminary clinical tests on the ETS20101 cancer drug have gone well and is on course to report more complete data by year end. Daniel says anti-depressant drug ETS6103 is also moving on and patients are expected to be enrolled soon with a view to having that data by the second half of 2014.
Is it just me or does anyone else find the flow chart presentation of these results very disjointed and confusing?
I would much prefer a straightforward properly written document. Anyway at least they seem to have plenty of cash for the foreseeable future!
Forgive me for complaining particularly as I don't have any money invested! However, I am thinking of investing, hence my interest.
Small free share float (University & Institutions hold aprox 85%)
Staff Share options exercise price @ £1 (2 yrs to run)
Funded till 2014 (no cash call)
Fledgeling , Phase 1 & Phase 2 Drugs Pipeline
New facility near Oxford
Drug Majors looking for new Drug Assets
The little-known UK biotech that's got David Cameron excited
On a brisk February morning earlier this year, the Prime Minister headed to Oxford.
He was on his way to visit a little-known British biotech.
What he discovered left him seriously excited.
You see, this tiny company is a world leader in a revolutionary approach to drug discovery.
David Cameron told the small gathering "Their use of pioneering science has the potential to deliver great results".
Click here for your free report
The "Google" of Pharmaceuticals
Put simply, this company has developed a unique "search engine" that could lead to breakthrough treatments for cancer, depression and hospital superbugs.
What's more, this groundbreaking technology is patent-protected.
In 2012 alone, FOUR of its drugs are entering clinical trials.
A wealth of newsflow is expected over the coming months and years.
Click here for your free report
When the clinical data is released, the results could be huge.
That's because ALL of these drugs have the potential to be a blockbuster if they make it onto the market.
One of the City's best kept secrets
This is not something you can sit back and ignore.
In fact, it's already on the radar screens of a handful of those who "know" this field.
This story could explode quickly...
I urge you to view this research immediately.
P.S. This is one of the best opportunities I've seen in the biotech sector EVER Take a look right away
Galvan Research And Trading Limited
Authorised and regulated by The Financial Services Authority
Tel +44 (0) 1872 262622
Fax +44 (0) 1872 265326
Email [email protected]
CMA House, Newham Road, Truro, Cornwall, TR1 2SU
Company No: 05054098
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.